8 completed, 4 unknown, 3 recruiting, 1 active not recruiting. 3 Not applicable, 3 Phase 4, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 4 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Chen Xiaoping: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models HAIC + Tislelizumab +lenvatinib - HCC, Precision Therapy | Phase 1 | Unknown | Chen Xiaoping | 30 | 2024-06-01 | 2024-06-17 |
| Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab - HCC | Phase 2 | Recruiting | Chen Xiaoping | 160 | 2024-06-01 | 2025-05-01 |
| Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. HAIC + Tirelizumab +lenvatinib +liver resection, liver resection - HCC | Phase 4 | Not yet recruiting | Chen Xiaoping | 312 | 2024-05-01 | 2024-03-15 |
| Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma PD-1 monoclonal antibody and lenvatinib, PD-1 monoclonal antibody - HCC | Phase 4 | Recruiting | Chen Xiaoping | 300 | 2024-04-01 | 2024-05-07 |
| Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. HAIC plus PD-1 inhibitors plus lenvatinib, PD-1 inhibitors plus lenvatinib - HCC | Phase 4 | Recruiting | Chen Xiaoping | 300 | 2024-04-01 | 2024-05-07 |
| Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma Liver Surgery - HCC - Hepatocellular Carcinoma | Completed | Chen Xiaoping | 3000 | 2022-01-15 | 2025-01-15 | |
| Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation PD-1 Inhibitors - Hepatocellular Carcinoma | Not applicable | Completed | Chen Xiaoping | 251 | 2021-01-01 | 2026-08-10 |
| ML Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma Rupture Peritoneal Metastasis - Peritoneal Metastasis | Completed | Chen Xiaoping | 522 | 2020-01-01 | 2023-10-26 | |
| Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy. Liver resection, Locoregional therapy - Hepatocellular Carcinoma | Not applicable | Active not recruiting | Chen Xiaoping | 1076 | 2019-12-01 | 2025-07-16 |
| Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma Hepatocellular Carcinoma, Liver Cirrhosis | Unknown | Chen Xiaoping | 1000 | 2019-08-01 | 2020-10-12 | |
| Chen's U-Suture Technique for Pancreaticojejunostomy Following Pancreaticoduodenectomy Chen's U-Suture, Classic pancreatic duct to mucosa - Pancreaticoduodenectomy | Not applicable | Unknown | Chen Xiaoping | 960 | 2019-06-24 | 2020-03-04 |
| Postoperative Adjuvant Therapy of HCC Based on PD-1 PD-1 inhibitors, TACE - Hepatocellular Carcinoma, RFS | Completed | Chen Xiaoping | 573 | 2019-02-01 | 2022-09-07 | |
| Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling Anti-PD-1 monoclonal antibody - Hepatocellular Carcinoma, Adjuvant Immunotherapy | Completed | Chen Xiaoping | 304 | 2019-02-01 | 2024-03-07 | |
| Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC Sintilimab, Lenvatinib - HCC, Adjuvant Therapy | Unknown | Chen Xiaoping | 620 | 2019-01-01 | 2024-06-17 | |
| VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy PD-1 monoclonal antibody and lenvatinib - HCC, Recurrence | Completed | Chen Xiaoping | 462 | 2019-01-01 | 2024-03-13 | |
| A Long-term Survival Analysis of Different Surgical Method in Early Hepatocellular Carcinoma liver resection - Long-term Effects of Cancer Treatment | Completed | Chen Xiaoping | 369 | 2015-02-14 | 2021-11-11 | |
| Comparison of Chen's U-suture Technique with Duct-to-Mucosa Anastomosis and Invagination Pancreaticojejunostomy After Pancreaticoduodenectomy Chen's U-suture technique, invagination, Duct-to-Mucosa - Pancreaticoduodenectomy | Completed | Chen Xiaoping | 5788 | 2014-01-01 | 2025-03-07 |
Carcinoma, Hepatocellular (8) · Recurrence (4) · Liver Cirrhosis (1)
lenvatinib (6) · Hepatectomy (4) · Immune Checkpoint Inhibitors (3) · spartalizumab (2) · sintilimab (1) · tislelizumab (1)
China (15)
Xiaoping Chen (4) · WanGuang Zhang (2) · WanGuang D Zhang (1) · Xiaoping Chen, Dr (1)